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A B S T R A C T
Purpose: The choice of initial anti-epileptic drug (AED) for elderly and younger adult patients with newly
diagnosed epilepsy was assessed.
Methods: The pattern of initial prescription of AEDs between 2000 and 2013 was retrospectively studied
in two community-dwelling cohorts, identiﬁed from the case records of Kuopio University Hospital
(KUH): elderly subjects (aged 65 or above at the time of diagnosis; n = 529) and a random sample of
younger adults (16–64 years old at the time of diagnosis; n = 201). Furthermore, nationwide register data
from the Social Insurance Institution of Finland were included in the analysis, from the years 2004 and
2012.
Results: Valproic acid (VPA) and carbamazepine (CBZ) were the most common initial AEDs both among
the elderly (49% and 31% of prescriptions, respectively) and for the patients in the younger-adults group
(19% and 61%, respectively) in the KUH data. In the nationwide register data, the most frequently used
initial AEDs for the elderly were VPA and oxcarbazepine. The selection of VPA was associated with higher
age (P < 0.001), myocardial infarction (P = 0.003), and stroke (P = 0.013). Lower probability of receiving
CBZ was observed with more advanced age (P < 0.001) and myocardial infarction (P = 0.002), whereas
diabetes (P = 0.018) and atrial ﬁbrillation (P = 0.045) predicted a higher probability.
Conclusion: First-generation AEDs are still the most commonly employed ﬁrst drugs for elderly patients
with newly diagnosed epilepsy in Finland. Age and comorbid conditions have an effect in the choice of
the initial AED treatment.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epileptic seizures and epilepsies constitute the third most
frequent neurological disorder after cerebrovascular disorders and
dementing illnesses in the elderly population of both Europe and
the United States [1,2]. Of all age groups, incidence rates of epilepsy
are at their highest in the elderly [1–3], and the absolute number of§ One of the authors of this paper is a member of the current editorial team of
Seizure. The supervision of the independent peer review process was undertaken
and the decision about the publication of this manuscript were made by other
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reelderly patients with epilepsy is only going to rise further as the
population continues to age [2].
The aetiology and clinical presentation of seizures in elderly
patients, and possibly also the prognosis, differ from those
observed in young adults. The clinical presentation of seizures
may cause challenges in differential diagnosis [4]. Seizures in the
elderly may be diagnosed as memory lapses or confusion, and the
option of diagnosing epilepsy may be missed or diagnosis delayed
[5,6]. The most common aetiologies of newly diagnosed seizures in
the elderly are ischaemic stroke (with a frequency among newly
diagnosed case with epilepsy of 40–50%), head injury (17%),
subarachnoid haemorrhage (8–24%), and intracranial haemor-
rhage (8%) [7]. However, 25–40% of the newly diagnosed cases
present no identiﬁable aetiology for the epilepsy [5]. The majority
of cases of newly diagnosed epilepsy in the elderly originally
manifest themselves as focal seizures [1,5].served.
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epileptic drugs (AEDs) is derived from populations below 65 years
of age, and randomised clinical trials in elderly patients are few in
number [8–11]. In older age groups, the use and selection of AEDs
may be complicated by altered pharmacokinetics and pharmaco-
dynamics, comorbidities, polypharmacy, physiological changes,
and concomitant functional impairment [7,12,13]. Furthermore,
adverse effects of AEDs may qualitatively and quantitatively differ
in the elderly from those seen in young adults [13]. Several sets of
guidelines for the treatment of epilepsy have been published in
recent years, but they give either very little or no guidance on the
treatment of elderly patients [13–16]. Studies in the United States
(US) have shown that, until recent years, phenytoin and other ﬁrst-
generation AEDs were the most commonly prescribed initial drugs
in the elderly [17–19].
The primary objective of the study reported upon here was to
assess the choice of ﬁrst AED in community-dwelling elderly
patients with newly diagnosed epilepsy in Finland. We also
compared the choice of initial AED between elderly and young
adults treated at the same hospital and conducted comparison
with data derived from a comprehensive national drug register.
Also, trends in the choice of initial AED were studied over time. Of
the second-generation AEDs, oxcarbazepine (which entered use in
1991), gabapentin (1999), lamotrigine (1999), topiramate (2002),
and levetiracetam (2006) have been approved for use as
monotherapy in epilepsy cases. However, only oxcarbazepine is
subject to full reimbursement as initial AED.
2. Material and methods
2.1. Population and setting
To assess patterns in prescription of AEDs in community-
dwelling elderly patients with newly diagnosed epilepsy, we used
two data sources: the case-record register of Kuopio University
Hospital (KUH) and nationwide register data maintained by the
Social Insurance Institution of Finland (SII). The Finnish population
(consisting of 5.4 million people in 2012) is stable and ethnically
homogenous. Those aged 65 years or over number about one
million.
KUH is one of ﬁve university hospitals in Finland. For epilepsy
patients, it serves as a secondary centre and also a national tertiary
referral centre. The population of the primary catchment area of
KUH is 250,000, with around 50,000 being age 65 or above.
National guidelines on the diagnosis and treatment of epilepsy
recommend that all patients with suspected seizures be referred to
a neurology department for evaluation [20].
2.1.1. Hospital cohort
Included in the study were community-dwelling patients who
had been diagnosed, on either an outpatient or inpatient basis, as
having epilepsy between 1.1.2000 and 31.12.2013; were aged
65 or above at the time of diagnosis of epilepsy; and had their AED
treatment started as monotherapy. All those patients from whom
data were available from at least one follow-up visit were included.
Excluded were patients who lived in institutions. In total,
529 patients meeting the inclusion criteria were identiﬁed.
Additionally, we identiﬁed seven patients in whom AED treatment
was begun as polytherapy.
A random sample of 201 patients was selected as the group of
young adults from the hospital case-record register by means of
the following criteria: new-onset focal epilepsy, diagnosis of
epilepsy between 2000 and 2013, patient age 16–64 years at the
time of diagnosis, and AED treatment begun as monotherapy.
From the KUH register we were able to review the case records
of the patients and gather detailed data on the patients’ medicaland demographic characteristics, including the aetiology of the
epilepsy and the seizure and epilepsy type. Number of seizures
before AED treatment and the initial AED were recorded also, as
were the patients’ place of residence and marital status.
2.1.2. Register data
To study the choice of the ﬁrst AED across the whole country,
we collected summary-form nationwide data from the drug
registers of the SII. The Drug Reimbursement Register was used to
identify non-institutionalised patients who were entitled to
reimbursement for AED medication after evaluation by the SII.
The evaluation is based on a medical certiﬁcate, prepared by a
neurologist, describing clinical, imaging and other laboratory
examinations conﬁrming the diagnosis of epilepsy. During the
study period, the following drugs were subject to full reimburse-
ment as a ﬁrst-line AED: carbamazepine, oxcarbazepine, phenyto-
in, and valproic acid. The Drug Prescription Register of the SII covers
information on drug class and the dispensing date for the
prescribed medicines delivered from pharmacies and subject to
reimbursement. Owing to the general health insurance covering all
Finnish citizens, the register has good coverage of outpatient
purchases of medications that require a prescription, including
AED medications. We extracted all patients aged 65 or above who
had received special reimbursement for the cost of AEDs due to
epilepsy in 2004 or 2012 and recorded their ﬁrst AED as
monotherapy during the years 2003–2004 or 2011–2012. Only
those subjects who had no record of AED purchases prior to those
years were included. In the 2004 cohort, 591 incident patients in
the whole of Finland and in the 2012 cohort 1081 incident patients
met these criteria and were included in the study (see Table 3).
2.2. Deﬁnitions
For purposes of the study, epilepsy was deﬁned as a disorder
with 1) at least two unprovoked (or reﬂex) seizures, occurring
>24 h apart; or 2) one unprovoked seizure and a probability of
further seizures similar to the general recurrence risk (at least 60%)
after two unprovoked seizures, occurring over the next 10 years on
account of, for example, underlying aetiology or status epilepticus
[21].
The epilepsy was categorised as focal, generalised, or unclassi-
ﬁed [22]. Epileptic seizures were classiﬁed as focal seizures,
generalised seizures, or unclassiﬁed seizures.
The aetiology of the epilepsy was recorded as stated in the case
records. Patients with acute symptomatic seizures – i.e., seizures
secondary to substance (including alcohol) abuse or withdrawal or
due to an acute illness [23] – were excluded.
2.3. Statistical analysis
The analysis of categorical data used a chi-square test, and a
Kruskal–Wallis test was used for categorical and ordinal variables.
Binary logistic regression analysis was conducted to identify
factors, such as age, sex, or comorbidity, that might have
inﬂuenced the choice of initial AED. The analysis was performed
for patients whose initial AED was VPA (n = 259) or CBZ (n = 164). It
was not conducted for other AEDs, because of small sample sizes.
The level for signiﬁcance was determined to be P < 0.05. All
statistical analyses were performed with Microsoft Excel and
SPSS 19.
2.4. Ethical considerations
This non-interventional study was based on individual-level
hospital patient data, and the corresponding authorisation for
using these data was received from the regulatory authority
Table 1
Clinical and demographic characteristics of the hospital-patient group with newly
diagnosed epilepsy.
Elderly Young adults
Sex
Women 253 48% Women 84 42%
Men 276 52% Men 117 58%
Age
65–69 121 23% 16–19 16 8%
70–74 143 27% 20–29 30 15%
75–79 99 19% 30–39 21 10%
80–84 112 21% 40–49 51 25%
85–89 46 9% 50–59 55 27%
90–94 8 2% 60–64 28 14%
Epilepsy type
Focal 527 100% Focal 201 100%
Unclassiﬁed 2 0% Unclassiﬁed 0 0%
Aetiology of epilepsy
Stroke 237 45% Stroke 33 16%
CNS tumour 54 10% CNS tumour 29 14%
Alzheimer’s disease 44 8% Alzheimer’s disease 0 0%
Head injury 10 2% Head injury 14 7%
CNS infection 6 1% CNS infection 7 3%
Other 9 2% Other 26 13%
Unknown 169 32% Unknown 92 46%
Total 529 201
CNS = central nervous system.
Table 2
Choice of the ﬁrst anti-epileptic drug in the elderly and in young adult patients
identiﬁed from the hospital.
Elderly Young adults
N n
Valproic acid 259 49% 39 19%
Carbamazepine 164 31% 122 61%
Levetiracetam 39 7% 12 6%
Phenytoin 20 4% 0 0%
Oxcarbazepine 15 3% 18 9%
Lamotrigine 15 3% 6 3%
Gabapentin 14 3% 2 1%
Pregabalin 2 0% 2 1%
Clobazam 1 0% 0 0%
Total 529 201
E. Bruun et al. / Seizure 31 (2015) 27–32 29responsible for the administration of said data at KUH. The data
received from the SII included no personal information of the
registered subjects.
3. Results
3.1. Characteristics of the community-dwelling epilepsy-diagnosed
hospital patients
In both the elderly and the young adults, there was a slight
preponderance of men over women (see Table 1). The most
commonly identiﬁable aetiologies of epilepsy in the elderly
patients were stroke, central nervous system tumour, and
Alzheimer’s disease. In all, 51% (n = 271) of the elderly patients
were married, 23% (n = 120) widowed, and 26% (n = 138) unmar-
ried/divorced.
3.2. The choice of the ﬁrst anti-epileptic drug for the hospital-group
patients
Among the hospital-group patients, there were statistically
signiﬁcantly differences in the choice of ﬁrst AED between the
elderly patients and young adults (P < 0.001; see Table 2). The
main difference was in the frequency of prescription of CBZ and
VPA.
The choice of the ﬁrst AED in the elderly patients varied
statistically signiﬁcantly (P < 0.001) with the age group (see Fig. 1).
With advancing age, the proportion of VPA increased while that of
CBZ decreased.
Predictive factors for the choice of CBZ and VPA as the initial
AED were analysed via binary logistic regression analysis (see
Table 3). Statistically signiﬁcant predictors for the choice of VPA as
initial AED were myocardial infarction and ischaemic stroke or
haemorrhage. Older patients were more likely to have VPA and less
likely to have CBZ as their initial AED. A predictor for lower
possibility of receiving CBZ as ﬁrst AED was myocardial infarction,
whereas diabetes and atrial ﬁbrillation predicted a higher
probability of receiving CBZ.
3.3. Number and characteristics of seizures prior to treatment start in
the elderly hospital-group patients
More than half of the elderly patients had experienced one or
two seizures before AED treatment. There were no statisticallyFig. 1. The choice of the ﬁrst anti-epilepsigniﬁcant differences in the total number of pre-treatment seizures
or in the number of focal generalised seizures between age groups.
A large majority of the elderly patients (427 patients, 81%) had
focal generalised seizures, and 137 (26%) of the patients overall hadtic drug, by the patient’s age group.
Table 3
Predictors of the choice of the initial anti-epileptic drug in the elderly patients with newly diagnosed epilepsy.
Valproic acid (n = 259) Carbamazepine (n = 164)
Variable Odds ratio 95% conﬁdence
interval
P-value Variable Odds ratio 95% conﬁdence
interval
P-value
Age 1.085 1.054–1.117 <0.001 Age 0.921 0.892–0.951 <0.001
Sex 1.443 0.996–2.091 0.053 Sex 0.682 0.457–1.017 0.060
Comorbidity Comorbidity
Diabetes 1.026 0.658–1.597 0.911 Diabetes 1.884 1.113–3.190 0.018
Hypertension 0.704 0.482–1.029 0.704 Hypertension 1.219 0.814–1.825 0.336
Osteoporosis 0.584 0.280–1.221 0.153 Osteoporosis 1.493 0.655–3.403 0.340
Myocardial infarction/
bypass/PTCA
2.110 1.284–3.469 0.003 Myocardial infarction/
bypass/PTCA
0.353 0.185–0.674 0.002
Atrial ﬁbrillation 0.704 0.482–1.029 0.070 Atrial ﬁbrillation 1.621 1.011–2.598 0.045
Any cancer 0.744 0.474–1.169 0.200 Any cancer 0.899 0.550–1.470 0.672
Ischaemic stroke/intracerebral
haemorrhage
1.549 1.098–2.187 0.013 Ischaemic stroke/
intracerebral haemorrhage
0.928 0.640–1.345 0.692
PTCA = percutaneous transluminal coronary angioplasty.
Fig. 2. The number of focal seizures prior to the start of anti-epileptic drug treatment.
E. Bruun et al. / Seizure 31 (2015) 27–3230focal seizures without generalisation (see Fig. 2). In 35 (7%) of the
patients, both focal seizures without generalisation and focal
generalised seizures had occurred before AED treatment. Because
the sets overlap, the percentages sum to above 100%. The number
of seizures prior to the start of AED treatment was statistically
signiﬁcantly higher (P < 0.001) among patients with focal seizures
without generalisation than the number in patients who experi-
enced focal seizures with generalisation.
3.4. Time trends of initial AED choices among hospital-group patients
and in the whole-country register data
There was statistically signiﬁcant (P < 0.001) variation in the
choice of AEDs over the observation period both in the elderly
hospital-group patients and in the full-country dataset (see Table 4).
In both hospital-patient and whole-country data, the prevalence
of choice of CBZ and phenytoin as the ﬁrst AED decreased and that of
choosing VPA and levetiracetam increased over the span of the
years examined. In the nationwide data, the use of oxcarbazepine
was more frequent than it was with the hospital patients.
4. Discussion
According to our population-based data, VPA has gained the
position of the most popular ﬁrst AED for elderly patients withnewly diagnosed epilepsy in Finland. Furthermore, the data based
on hospital patient records showed that, with advancing patient
age, the proportion of VPA to all AEDs prescribed rose. In
comparison with practices in the US [17,18], the use of phenytoin
was quite limited in Finland. The Finnish guidelines on the
treatment of epilepsy [20] state that, because of its adverse effects
and the challenges in pharmaco-kinetics, phenytoin should not be
used as primary AED for adult patients. According to the relevant
guideline, VPA is not recommended as the ﬁrst choice for focal
epilepsy. However, it may have been favoured for our patients on
account of its lack of adverse cardiac effects, hepatic metabolic
enzyme induction, lower risk of drug interactions relative to CBZ,
and good tolerability in the elderly [7,12].
In the hospital-based cohort, there were differences in the
choice of initial AED between the elderly patients and young adults
treated: in total, 61% of the latter were prescribed CBZ. This
frequency is twice that for the elderly. In young adults, VPA was the
second most commonplace initial choice, followed by oxcarbaze-
pine. The choices for young adults are in accordance with other
studies’ ﬁndings [13].
According to our study, concomitant disorders seemed to have
some impact on the choice of initial AED: CBZ use was started less
often in cases of patients with cardiac disorders, and VPA was
favoured for patients with diagnosed myocardial infarction or
stroke. In the binary logistic regression analysis, cardiac disorders
Table 4
The choice of the ﬁrst anti-epileptic drug during different time periods in the elderly hospital-based with epilepsy and in the national register data (the ‘Other AED’ category
includes the anti-epileptic clobazam in the KUH data and clobazam, clonazepam, lacosamide, tiagabine, and topiramate in the whole-country data).
KUH 2000–2004 2005–2009 2010-2013 National register 2004 2012
N N N N N
Valproic acid 45 28% 110 57% 104 60% Valproic acid 146 25% 363 34%
Carbamazepine 82 51% 52 27% 30 17% Carbamazepine 150 25% 179 17%
Levetiracetam 1 1% 11 6% 27 16% Levetiracetam 0 0% 108 10%
Phenytoin 17 10% 3 2% 0 0% Phenytoin 83 14% 26 2%
Oxcarbazepine 3 2% 6 3% 6 3% Oxcarbazepine 185 31% 278 26%
Lamotrigine 11 7% 0 0% 4 2% Lamotrigine 8 1% 11 1%
Gabapentin 3 2% 10 5% 1 1% Gabapentin 11 2% 17 2%
Pregabalin 0 0% 1 1% 1 1% Pregabalin 0 0% 78 7%
Other AED 0 0% 0 0% 1 1% Other AED 8 1% 21 2%
Total 162 193 174 Total 591 1081
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both CBZ and VPA. VPA has been reported to be associated with
lower risk of myocardial infarction and stroke as compared with
CBZ [24,25]. Because of the high prevalence of cardiovascular
comorbidity in the elderly patients with epilepsy and risk of drug
interactions with CBZ, VPA was favoured over CBZ in the oldest age
groups. The reason for favouring of CBZ in patients with diabetes
remains obscure.
Most of the new-onset seizures in the elderly have focal onset
[5]. In the hospital-patient cohort, almost all cases had a diagnosis
of focal epilepsy. Cerebrovascular disorders were the most
common aetiology of epilepsy in our patients, a ﬁnding consistent
with previous observations [7]. In about one third of cases, the
aetiology of the epilepsy remained unknown.
A third of the patients identiﬁed from the hospital had
experienced a single seizure and 28% two seizures before AED
treatment commenced, which indicates an active approach to the
treatment of epilepsy in the elderly. Patients with focal generalised
seizures usually had only one (36%) or two (30%) seizures before
AED treatment, whereas two thirds of the patients with focal
seizures without generalisation had experienced more than two
seizures before treatment commenced. This probably is linked to
difﬁculties in the diagnosis of epilepsy in the elderly. If focal
seizures without generalisation are not recognised as epileptic in
nature by the patients or family or the symptoms do not cause
signiﬁcant impairment to the patient’s life, consultation of a
physician and also diagnosis may be delayed.
The choices for initial AEDs for community-dwelling elderly
patients with epilepsy, identiﬁed from the hospital, deviated from
the prescription pattern for the country at large with respect to use
of CBZ and oxcarbazepine: according to the whole-country register
data, oxcarbazepine, which was approved for use as monotherapy
more than 20 years ago in Finland, was more popular than CBZ.
Oxcarbazepine is more strongly associated with hyponatraemia
than CBZ is [7], which may account for its lower popularity for
elderly hospital-group patients. Internationally, CBZ remains one
of the AEDs most commonly used for the elderly [17,26].
Pugh et al. [17,27] observed some time-related trends in the
choice of AEDs in the United States: from 2000 to 2006, the use of
phenytoin declined and the frequency of use of CBZ, gabapentin,
and VPA remained quite stable, but the use of levetiracetam
increased. In our study, VPA and levetiracetam became more
popular whilst the use of CBZ declined over the last 12 years. With
the exception of levetiracetam, second-generation AEDs were used
only in the minority of cases in both the elderly-hospital-patients
cohort and the nationwide material, despite the fact that
gabapentin and lamotrigine have shown established evidence of
efﬁcacy in elderly patients [8,10,11]. The prescription pattern in
Finland most probably is related to the fact that, with the exceptionof oxcarbazepine, second-generation AEDs are not subject to full
reimbursement as ﬁrst-line drugs.
Our ﬁndings are based on a community-dwelling hospital
cohort and also on national register data, which should provide
some guarantee as to the population-based results. Comparison of
the ﬁndings between these data sources shows some inconsis-
tencies – with regard to, for example, drug choices. The patients
identiﬁed from the hospital may represent a selected group,
although specialist evaluation at outpatient clinics is recom-
mended by the national guidelines [20]. Our database covering
hospital patients is far more detailed than are the national register
data. We were able to review the case records of the hospital
patients; accordingly, the senior authors could conﬁrm the
correctness of the data. This was not possible with the data
obtained from the national registers.
Management of epilepsy in the elderly requires an understand-
ing of aetiology and pharmacological factors that are unique to
older persons [5,7]. The choice of AED should be based on
assessment of seizure type, concomitant medications, and coex-
isting diseases. Because newer AEDs may have fewer or less severe
interactions and side effects when compared to standard AEDs,
they might be more suitable as a treatment of ﬁrst choice for the
elderly [7,28].
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